Abstract
Increased levels of activated T cells are a hallmark of the chronic stage of human immunodeficiency virus (HIV) infection and are highly correlated with HIV disease progression. We evaluated chloroquine (CQ) as a potential therapy to reduce immune activation during HIV infection. We found that the frequency of CD38(+) HLA-DR(+) CD8 T cells, as well as Ki-67 expression in CD8 and CD4 T cells, was significantly reduced during CQ treatment. Our data indicate that treatment with CQ reduces systemic T-cell immune activation and, thus, that its use may be beneficial for certain groups of HIV-infected individuals.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / drug effects
-
CD8-Positive T-Lymphocytes / immunology
-
Cells, Cultured
-
Chloroquine / administration & dosage*
-
Chronic Disease / therapy
-
Down-Regulation / drug effects*
-
HIV Infections / drug therapy*
-
HIV Infections / immunology*
-
Humans
-
Ki-67 Antigen / immunology
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / immunology
-
Lymphocyte Activation / drug effects
Substances
-
Ki-67 Antigen
-
Chloroquine